Black Diamond Therapeutics Q2 net loss narrows year over year
BDTX•Outlook
- Company expects to provide an update on silevertinib Phase 2 trial and FDA feedback in Q4 2026.
- Company expects to initiate randomized portion of silevertinib Phase 2 trial in GBM in Q4 2026.
- Black Diamond expects cash and investments to fund operations into 2H 2028.
Overview
- US oncology developer's Q2 net loss narrowed year over year.
- Company presented positive Phase 2 silevertinib results in NSCLC at ASCO 2026.
- Cash position expected to fund operations into 2H 2028.
Result drivers
- Clinical trial progress - Co said positive Phase 2 silevertinib results in non-classical EGFR-mutant NSCLC, including high CNS response rates and no new brain metastases, drove clinical momentum.
- R&D expenses - Decrease in R&D expenses attributed to progression of silevertinib NSCLC trial, partially offset by increased spend on GBM trial.
- Safety profile - No new safety signals for silevertinib; severe adverse event rate reduced after dose reduction, with maintained or deepened responses.
